Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from July 14, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 12, 2025 — -8.7% at the close.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted
$104.51 Published $117.05 Target $95.41 Window close $109.50 Peak
$103.50 – $105.50Entry zone — fair-value band
$104.51Published — price the day we called it
$117.05Target — the price the thesis aimed for
$109.50Peak — highest point inside the window, not a realized return
$95.41Window close — end-of-window price, context only

What happened

Partial

Reached 40% of the predicted growth at its peak, without hitting the target.

At window close
-8.7%
realized, from the publication price to the last close inside the window
Peak gain
+4.8%
peak, from the publication price — not a realized return
S&P 500, same window
+4.8%
SPY over the identical days, dividend-adjusted
Window close
$95.41
last close inside the window, ended October 12, 2025
Peak price
$109.50
peak on September 9, 2025 — not a realized return
Days to target
—

The thesis — published July 14, 2025

Predicted growth
+12%
over the measurement window
Target price
$117.05
the price the thesis aimed for
Entry zone
$103.50 – $105.50
the fair-value band we waited for
Price at publication
$104.51
published July 14, 2025
Confidence
85%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

U.S. health regulators just gave wider approval for FARAPULSE, a heart-treatment device made by Boston Scientific. That green light should create a new flow of sales at the same moment the stock price looks beaten down after a recent slide. Trading activity shows far fewer people willing to sell and many more stepping in to buy. With doctors starting to use the product and medical-technology funds likely to return, we see the shares climbing about 12% over the next three months while the company’s other new products keep interest high.

Primary drivers

  • Wider FDA approval for FARAPULSE could add a new stream of heart-care sales.
  • Stock looks oversold; heavy recent buying hints it may soon change direction.
  • Very positive market mood and strong past returns attract big professional buyers.
  • Many products in development mean growth is not tied to just one device.

How it played out

BSX: target missed after a 4.8% peak gain

Lyra published BSX at $104.51 on 2025-07-14 with about 12% expected growth over the short term. The thesis pointed to wider U.S. approval for FARAPULSE, an oversold setup with heavy buying, positive market mood, professional buyer interest, and a broader product pipeline.

Inside the window, BSX rose to $109.50 on 2025-09-09. That was a 4.8% peak gain, but it stayed below the $117.05 target. It never got there. The window ended at $95.41 on 2025-10-12, so the published thesis only partially played out.

What happened during the window

On 2025-07-23, Investor's Business Daily reported Boston Scientific's second-quarter results, including $5.06 billion in sales and adjusted earnings of $0.75 per share. The same article said Farapulse U.S. growth was 117%.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals